MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 25, 2018

Study Completion Date

December 31, 2019

Conditions
Minimal Residual DiseaseDonor Lymphocyte InfusionHematopoietic Stem Cell TransplantationRelapse
Interventions
BIOLOGICAL

donor lymphocyte infusion

DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02673008 - MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | Biotech Hunter | Biotech Hunter